[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2192929B1 - IMPROVED PROCEDURE FOR OBTAINING STABLE AND GASTRORRESISTENT OMEPRAZOL PELLETS, PELLETS AS WELL OBTAINED AND APPLICATIONS. - Google Patents

IMPROVED PROCEDURE FOR OBTAINING STABLE AND GASTRORRESISTENT OMEPRAZOL PELLETS, PELLETS AS WELL OBTAINED AND APPLICATIONS.

Info

Publication number
ES2192929B1
ES2192929B1 ES200100825A ES200100825A ES2192929B1 ES 2192929 B1 ES2192929 B1 ES 2192929B1 ES 200100825 A ES200100825 A ES 200100825A ES 200100825 A ES200100825 A ES 200100825A ES 2192929 B1 ES2192929 B1 ES 2192929B1
Authority
ES
Spain
Prior art keywords
pellets
applications
gastrorresistent
omeprazol
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200100825A
Other languages
Spanish (es)
Other versions
ES2192929A1 (en
Inventor
Luis Carvajal Martin
Juan Carlos Asensio Asensio
Francisco J. Sevilla Tirado
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Belmac SA
Original Assignee
Laboratorios Belmac SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Belmac SA filed Critical Laboratorios Belmac SA
Priority to ES200100825A priority Critical patent/ES2192929B1/en
Publication of ES2192929A1 publication Critical patent/ES2192929A1/en
Application granted granted Critical
Publication of ES2192929B1 publication Critical patent/ES2192929B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Procedimiento mejorado para la obtención de pellets de omeprazol estables y gastrorresistentes, pellets así obtenidos y aplicaciones. El procedimiento comprende: (a) selección y fabricación de "neutros"; (b) adhesión del principio activo a dichos neutros para obtener "núcleos activos"; (c) aislamiento de dichos núcleos activos para obtener "núcleos activos aislados"; y (d) recubrimiento de dichos núcleos activos aislados para obtener "núcleos activos gastrorresistentes". Dichos pellets son los referidos "núcleos activos gastrorresistentes" obtenidos por dicho procedimiento. Aplicación en medicina humana y veterinaria.Improved procedure for obtaining stable and gastro-resistant omeprazole pellets, pellets thus obtained and applications. The process comprises: (a) selection and manufacture of "neutrals"; (b) adhesion of the active substance to said neutrals to obtain "active nuclei"; (c) isolation of said active cores to obtain "isolated active cores"; and (d) coating said isolated active cores to obtain "gastro-resistant active cores". Said pellets are those referred to as "gastro-resistant active nuclei" obtained by said procedure. Application in human and veterinary medicine.

ES200100825A 2001-04-06 2001-04-06 IMPROVED PROCEDURE FOR OBTAINING STABLE AND GASTRORRESISTENT OMEPRAZOL PELLETS, PELLETS AS WELL OBTAINED AND APPLICATIONS. Expired - Fee Related ES2192929B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES200100825A ES2192929B1 (en) 2001-04-06 2001-04-06 IMPROVED PROCEDURE FOR OBTAINING STABLE AND GASTRORRESISTENT OMEPRAZOL PELLETS, PELLETS AS WELL OBTAINED AND APPLICATIONS.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100825A ES2192929B1 (en) 2001-04-06 2001-04-06 IMPROVED PROCEDURE FOR OBTAINING STABLE AND GASTRORRESISTENT OMEPRAZOL PELLETS, PELLETS AS WELL OBTAINED AND APPLICATIONS.

Publications (2)

Publication Number Publication Date
ES2192929A1 ES2192929A1 (en) 2003-10-16
ES2192929B1 true ES2192929B1 (en) 2005-02-16

Family

ID=29724673

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200100825A Expired - Fee Related ES2192929B1 (en) 2001-04-06 2001-04-06 IMPROVED PROCEDURE FOR OBTAINING STABLE AND GASTRORRESISTENT OMEPRAZOL PELLETS, PELLETS AS WELL OBTAINED AND APPLICATIONS.

Country Status (1)

Country Link
ES (1) ES2192929B1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0519144B1 (en) * 1991-06-21 1997-08-13 Ilsan Ilac Ve Hammaddeleri Sanayi A.S. New galenic process for omeprazole containing pellets
FR2692146B1 (en) * 1992-06-16 1995-06-02 Ethypharm Sa Stable compositions of gastro-protected omeprazole microgranules and process for obtaining them.
ES2047451B1 (en) * 1992-07-10 1994-10-01 Sint Quimica Sa PROCEDURE FOR THE PREPARATION OF A STABLE ORAL PHARMACEUTICAL COMPOSITION.
ES2087823B1 (en) * 1994-07-13 1997-02-16 Estudes Et Richerches Pharma E FORMULATION OF GASTRORESISTENT MICROGRANULES OF OMEPRAZOLE AND ITS MANUFACTURING PROCEDURE.

Also Published As

Publication number Publication date
ES2192929A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
TW200630326A (en) Chemical compounds
NO20012222D0 (en) Pharmaceutical formulation including omeprazole
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
GEP20063895B (en) Platinum derivative pharmaceutical formulations
BR0312563A (en) Lasofoxifene tablet and its coating
SG127738A1 (en) Heterocyclic compounds based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, pharmaceutical preparations containing these compounds
AR012698A1 (en) PHARMACEUTICAL FORMULATION OF OMEPRAZOLE
HRP20040107B1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
AR052238A1 (en) FORMULATION OF STABLE TABLETS
BRPI0412232A (en) agrochemical formulations
ATE326264T1 (en) PHARMACEUTICAL FORMULATIONS WITH CONTROLLED RELEASE OF ACTIVE INGREDIENTS CONTAINING LACTIC ACID POLYMER AND THEIR PRODUCTION
CY1105019T1 (en) SUBSTITUTED C-IMIDAZO-[1,2-A]PYRIDIN-3-YL-METHYLAMINES
BRPI0409532A (en) pharmaceutical composition, lyophilized formulation, manufacturing method of pharmaceutical composition, lyophilized formulation manufacturing method and article of manufacture
UY28733A1 (en) CHEMICAL COMPOUNDS
DE60215313D1 (en) INDOIND DERIVATIVES AND THEIR USE AS GNRH ANTAGONISTS
TW200630352A (en) Chemical compounds
SE0103819D0 (en) Chemical compounds
ES2192929B1 (en) IMPROVED PROCEDURE FOR OBTAINING STABLE AND GASTRORRESISTENT OMEPRAZOL PELLETS, PELLETS AS WELL OBTAINED AND APPLICATIONS.
BRPI0415870B8 (en) low dose tablets with polymer network and their preparation process
NO20024363D0 (en) New LHRH antagonists, their production and use as a drug
ATE395048T1 (en) CONTROLLED RELEASE BETAHISTINE PREPARATIONS
ECSP045232A (en) ORAL DOSAGE FORM, PROCEDURE TO PREPARE IT AND USE OF A PHARMACEUTICALLY ACCEPTABLE WEAK BASE OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE OF THE SAME TO PREPARE SUCH ORAL DOSAGE FORM
AR033896A1 (en) GABOXADOL GRANULATED PREPARATIONS.
SE0101692D0 (en) Compounds
ATE346510T1 (en) JELLY SUGAR AND METHOD FOR THE PRODUCTION THEREOF

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20031016

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2192929B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180807